RhumbLine Advisers
TLX

RhumbLine Advisers’s Telix Pharmaceuticals TLX Stock Holding History

RhumbLine Advisers’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.3K Sell
7,918
-1,905
-19% -$19.4K ﹤0.01% 3558
2026
Q1 		$94K Sell
9,823
-964
-9% -$7.34K ﹤0.01% 3438
2025
Q4 		$80.8K Buy
10,787
+8,208
+318% +$79K ﹤0.01% 3540
2025
Q3 		$24.7K Buy
2,579
+1,392
+117% +$17.1K ﹤0.01% 3753
2025
Q2 		$19.2K Buy
1,187
+41
+4% +$688 ﹤0.01% 3800
2025
Q1 		$19.2K Buy
+1,146
New +$20K ﹤0.01% 3749

Other funds holding TLX

Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

RhumbLine Advisers's TLX Position: Q2 2026 in Review

RhumbLine Advisers reduced its Telix Pharmaceuticals (TLX) stake by 19% in Q2 2026, selling an estimated $19.4K and leaving 7,918 shares worth $91.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3558.

RhumbLine Advisers first reported a position in TLX in Q1 2025 and has held it in 6 quarters since. The position peaked at $94K in Q1 2026. 56 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • RhumbLine Advisers held 7,918 shares of Telix Pharmaceuticals worth $91.3K as of Q2 2026.
  • RhumbLine Advisers sold 1,905 Telix Pharmaceuticals shares in Q2 2026, an estimated $19.4K.
  • Telix Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3558 holding.
  • RhumbLine Advisers first reported a position in Telix Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • RhumbLine Advisers's Telix Pharmaceuticals position peaked at $94K in Q1 2026.
  • 56 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.